C72.20
BillableMalignant neoplasm of unspecified olfactory nerve
Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)
Is C72.20 an HCC code?
Yes. C72.20 maps to Lung and Other Severe Cancers under the CMS-HCC V28 risk adjustment model (and Lymphoma and Other Cancers under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for C72.20
For C72.20 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C72.20 during that encounter — not just copy-forwarded from a problem list.
What This Code Means
C72.20 is the ICD-10-CM diagnosis code for malignant neoplasm of unspecified olfactory nerve. This code represents a cancer that has developed in the olfactory nerve (the nerve responsible for the sense of smell), but the specific location along the nerve has not been identified. This is a rare type of brain/nerve cancer. C72.20 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of eye, brain and other parts of central nervous system (c69-c72).
Under the CMS-HCC V28 risk adjustment model, C72.20 maps to Lung and Other Severe Cancers (HCC 20) with a community, non-dual, aged base RAF weight of 0.000. Under the older CMS-HCC V24 model, C72.20 maps to Lymphoma and Other Cancers (HCC 10) with a community, non-dual, aged base RAF weight of 0.675. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
Verify documentation specifies olfactory nerve involvement; if the site is documented as right or left, use C72.21 or C72.22 instead of the unspecified code. Because C72.20 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C72.20 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •Verify documentation specifies olfactory nerve involvement; if the site is documented as right or left, use C72.21 or C72.22 instead of the unspecified code
- •This code requires a secondary code for histological type (8th character) to fully specify the malignancy; ensure pathology reports are reviewed for tumor classification
Clinical Significance
Malignant neoplasm of the unspecified olfactory nerve is a rare cancer of cranial nerve I that typically presents as esthesioneuroblastoma (olfactory neuroblastoma). This tumor's proximity to the cribriform plate and anterior cranial fossa makes it particularly dangerous, often requiring combined craniofacial surgical approaches. The 'unspecified' laterality designation indicates incomplete documentation that should prompt a provider query.
Documentation Requirements
- ✓Pathology report confirming malignancy and histological type (most commonly esthesioneuroblastoma)
- ✓Laterality — query provider if right or left side is not specified to use C72.21 or C72.22
- ✓Kadish staging or modified Kadish staging if available
- ✓Extent of disease including any intracranial extension
- ✓Current treatment status and modality (surgery, radiation, chemotherapy)